These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 35695526)
1. Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates. Montero MM; Domene-Ochoa S; López-Causapé C; López-Montesinos I; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Ferrer Alapont L; Grau S; Oliver A; Horcajada JP Microbiol Spectr; 2022 Jun; 10(3):e0089222. PubMed ID: 35695526 [TBL] [Abstract][Full Text] [Related]
2. Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model. Montero MM; Domene-Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Ferrer-Alapont L; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP Sci Rep; 2021 Nov; 11(1):22178. PubMed ID: 34773066 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study. Navarrete-Rouco ME; Luque S; Sorlí L; Benítez-Cano A; Roberts JA; Grau S Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):561-566. PubMed ID: 35657580 [TBL] [Abstract][Full Text] [Related]
5. Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance. Tait JR; Harper M; Cortés-Lara S; Rogers KE; López-Causapé C; Smallman TR; Lang Y; Lee WL; Zhou J; Bulitta JB; Nation RL; Boyce JD; Oliver A; Landersdorfer CB Antimicrob Agents Chemother; 2023 Aug; 67(8):e0041423. PubMed ID: 37428034 [TBL] [Abstract][Full Text] [Related]
6. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016 and 2019 in China. Yu W; Zhang H; Zhu Y; Jia P; Xu Y; Yang Q Int J Antimicrob Agents; 2023 Apr; 61(4):106741. PubMed ID: 36736928 [TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital. López-Calleja AI; Morilla Morales E; Nuñez Medina R; Fernández Esgueva M; Sahagún Pareja J; García-Lechuz Moya JM; Ferrer Cerón I; Viñuelas Bayon J; Rezusta López A Rev Esp Quimioter; 2019 Feb; 32(1):68-72. PubMed ID: 30547503 [TBL] [Abstract][Full Text] [Related]
8. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa. Pilmis B; Petitjean G; Lesprit P; Lafaurie M; El Helali N; Le Monnier A; Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1457-1461. PubMed ID: 31073653 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model. Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497 [TBL] [Abstract][Full Text] [Related]
10. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia. Henderson A; Tan E; McCarthy KL; Paterson DL Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710 [TBL] [Abstract][Full Text] [Related]
11. Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy. Fernández-Esgueva M; López-Calleja AI; Mulet X; Fraile-Ribot PA; Cabot G; Huarte R; Rezusta A; Oliver A Enferm Infecc Microbiol Clin (Engl Ed); 2020 Dec; 38(10):474-478. PubMed ID: 32143893 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16. Walkty A; Adam H; Baxter M; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG J Antimicrob Chemother; 2018 Mar; 73(3):703-708. PubMed ID: 29244121 [TBL] [Abstract][Full Text] [Related]
13. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015. Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073 [TBL] [Abstract][Full Text] [Related]
14. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. Shortridge D; Castanheira M; Pfaller MA; Flamm RK Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483953 [TBL] [Abstract][Full Text] [Related]
15. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). Pfaller MA; Bassetti M; Duncan LR; Castanheira M J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526 [TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones. Gomis-Font MA; Cabot G; López-Argüello S; Zamorano L; Juan C; Moyá B; Oliver A J Antimicrob Chemother; 2022 Mar; 77(4):957-968. PubMed ID: 35084040 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar. Sid Ahmed MA; Abdel Hadi H; Hassan AAI; Abu Jarir S; Al-Maslamani MA; Eltai NO; Dousa KM; Hujer AM; Sultan AA; Soderquist B; Bonomo RA; Ibrahim EB; Jass J; Omrani AS J Antimicrob Chemother; 2019 Dec; 74(12):3497-3504. PubMed ID: 31504587 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece. Galani I; Papoutsaki V; Karantani I; Karaiskos I; Galani L; Adamou P; Deliolanis I; Kodonaki A; Papadogeorgaki E; Markopoulou M; Maraki S; Damala M; Prifti E; Vagiakou E; Petinaki E; Fountoulis K; Tsiplakou S; Kirikou H; Souli M; Antoniadou A; Giamarellou H J Antimicrob Chemother; 2020 Aug; 75(8):2164-2172. PubMed ID: 32449909 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model. Montero M; VanScoy BD; López-Causapé C; Conde H; Adams J; Segura C; Zamorano L; Oliver A; Horcajada JP; Ambrose PG Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530842 [TBL] [Abstract][Full Text] [Related]
20. Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia. Motos A; Li Bassi G; Pagliara F; Fernandez-Barat L; Yang H; Aguilera Xiol E; Senussi T; Idone FA; Travierso C; Chiurazzi C; Amaro R; Yang M; Bobi J; Rigol M; Nicolau DP; Frigola G; Cabrera R; Ramirez J; Pelosi P; Blasi F; Antonelli M; Artigas A; Vila J; Kollef M; Torres A Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]